Table 4.
Cardiovascular Event IRs per 1000 person‐years
| Transdermal treatment | PY/1000 | Events | IR | Unadjusted HR | |
|---|---|---|---|---|---|
| Composite cardiovascular end point* | Former | 139.8 | 2103 | 15.04 | 1.00 (ref) |
| Current | 36.9 | 434 | 11.77 | 0.78 (0.7–0.87) | |
| No use | 631.2 | 10108 | 16.01 | 1.07 (1.02–1.12) | |
| MI | Former | 144.6 | 1210 | 8.37 | 1.00 (ref) |
| Current | 37.9 | 246 | 6.49 | 0.78 (0.68–0.90) | |
| No use | 651.9 | 6030 | 9.25 | 1.12 (1.05–1.19) | |
| Stroke | Former | 148.1 | 618 | 4.17 | 1.00 (ref) |
| Current | 38.5 | 131 | 3.41 | 0.84 (0.69–1.01) | |
| No use | 666.7 | 3047 | 4.57 | 1.11 (1.02–1.22) | |
| VTE † | Former | 148.3 | 558 | 3.76 | 1.00 (ref) |
| Current | 38.4 | 106 | 2.76 | 0.69 (0.56–0.85) | |
| No use | 670.1 | 2361 | 3.52 | 0.91 (0.83–1.00) |
| Intramuscular Treatment | |||||
|---|---|---|---|---|---|
| Composite cardiovascular endpoint* | Former | 117.8 | 1902 | 16.14 | 1.00 (ref) |
| Current | 68.9 | 975 | 14.15 | 0.88 (0.82–0.95) | |
| No use | 621.2 | 9768 | 15.72 | 0.98 (0.93–1.03) | |
| MI | Former | 121.8 | 1123 | 9.22 | 1.00 (ref) |
| Current | 70.5 | 575 | 8.16 | 0.90 (0.81–0.99) | |
| No use | 642.2 | 5788 | 9.01 | 0.99 (0.93–1.05) | |
| Stroke | Former | 124.9 | 569 | 4.56 | 1.00 (ref) |
| Current | 72.0 | 252 | 3.50 | 0.80 (0.69–0.93) | |
| No use | 656.4 | 2975 | 4.53 | 1.03 (0.94–1.13) | |
| VTE † | Former | 125.4 | 461 | 3.68 | 1.00 (ref) |
| Current | 71.9 | 228 | 3.17 | 0.83 (0.71–0.97) | |
| No use | 659.4 | 2336 | 3.54 | 0.94 (0.85–1.04) | |
IR indicates incidence rate; and MI, myocardial infarction.
*
Composite cardiovascular end point was composed of MI, ischemic stroke, and VTE.
†
VTE: venous thromboembolism, composed of pulmonary embolism and deep vein thrombosis.